Short Interest in Mural Oncology plc (NASDAQ:MURA) Drops By 25.2%

Mural Oncology plc (NASDAQ:MURA) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 396,800 shares, a drop of 25.2% from the January 15th total of 530,200 shares. Based on an average daily trading volume, of 206,900 shares, the days-to-cover ratio is currently 1.9 days. Approximately 2.6% of the company’s stock are sold short.

Institutional Trading of Mural Oncology

A number of hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC lifted its position in shares of Mural Oncology by 2.6% in the third quarter. Geode Capital Management LLC now owns 190,056 shares of the company’s stock valued at $595,000 after buying an additional 4,731 shares during the last quarter. Northern Trust Corp lifted its position in shares of Mural Oncology by 22.0% in the fourth quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock valued at $129,000 after buying an additional 7,197 shares during the last quarter. FMR LLC lifted its position in shares of Mural Oncology by 124.7% in the third quarter. FMR LLC now owns 20,580 shares of the company’s stock valued at $64,000 after buying an additional 11,423 shares during the last quarter. Commerce Bank acquired a new stake in shares of Mural Oncology in the third quarter valued at approximately $39,000. Finally, Jane Street Group LLC acquired a new stake in shares of Mural Oncology in the fourth quarter valued at approximately $68,000. 80.21% of the stock is owned by institutional investors and hedge funds.

Mural Oncology Stock Up 0.7 %

MURA stock traded up $0.03 during mid-day trading on Friday, reaching $4.29. The company had a trading volume of 67,600 shares, compared to its average volume of 182,120. Mural Oncology has a 52 week low of $2.87 and a 52 week high of $5.62. The stock has a 50 day simple moving average of $3.70 and a two-hundred day simple moving average of $3.52.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Mural Oncology in a report on Monday, November 11th.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.